Inclusion Criteria:

          -  Provision of signed and dated, written informed consent prior to any study specific
             procedures, sampling and analyses

             o If a patient declines to participate in any voluntary exploratory research and/or
             genetic component of the study, there will be no penalty or loss of benefit to the
             patient and he/she will not be excluded from other aspects of the study

          -  Aged at least 18 years at time of signing informed consent

          -  A pathologic (histology or cytology) confirmed diagnosis of epithelial ovarian cancer,
             including fallopian or primary peritoneal cancer

             o low grade serous histology is excluded

          -  Radiographic evidence of recurrent epithelial ovarian cancer (ovarian, fallopian tube,
             or primary peritoneal cancer) that has become "platinum-resistant," defined as
             progression of disease within 6 months from the last dose of platinum-based
             chemotherapy, or platinum refractory

          -  Not a candidate for cytoreductive surgery

          -  Measurable disease (at least one lesion that can be accurately assessed repeatedly by
             CT or MRI) as evidenced on pre-treatment baseline CT of Chest/Abdomen/Pelvis, MRI, or
             PET/CT, or evaluable disease (defined as anything non-measurable- pleural effusions,
             lesions <1cm, etc).

          -  World Health Organization (WHO) performance status 0-1 with no deterioration over the
             previous 2 weeks and minimum life expectancy of 12 weeks

          -  Up to 3 lines of prior cytotoxic chemotherapy

          -  Previously received bevacizumab

          -  Has not received weekly paclitaxel-containing regimen, EXCEPT for in the front-line
             setting

             o Patients with prior paclitaxel reactions may be enrolled if they have been
             successfully re-treated with steroid pre-medication in the past

          -  Patients must use adequate contraceptive measures, should not be breast feeding and
             must have a negative pregnancy test prior to start of dosing (within 7 days) if of
             child-bearing potential or must have evidence of non-child-bearing potential by
             fulfilling one of the following criteria at screening:

               -  Post-menopausal defined as aged more than 50 years and amenorrhea for at least 12
                  months following cessation of all exogenous hormonal treatments

               -  Documentation of irreversible surgical sterilization by hysterectomy, bilateral
                  oophorectomy or bilateral salpingectomy but not tubal ligation

          -  For women of childbearing potential: agreement to remain abstinent (refrain from
             heterosexual intercourse) or use contraceptive methods with a failure rate of < 1% per
             year during the treatment period and for 28 days after the last dose of study
             treatment. Women must refrain from donating eggs during this same period.

        Exclusion Criteria:

          -  Treatment with any of the following:

               -  Any investigational agents or study drugs from a previous clinical study within
                  28 days of the first dose of study treatment

               -  Any other chemotherapy, immunotherapy or anticancer agents within 14 days of the
                  first dose of study treatment

               -  Potent inhibitors or inducers or substrates of CYP3A4 or substrates of CYP2D6
                  within 2 weeks before the first dose of study treatment (3 weeks for St John's
                  Wort)

               -  Any prior exposure to Ipatasertib

          -  Major surgery (excluding placement of vascular access) within 4 weeks of the first
             dose of study treatment

          -  Radiotherapy with a wide field of radiation within 4 weeks or radiotherapy with a
             limited field of radiation for palliation within 2 weeks of the first dose of study
             treatment

          -  With the exception of alopecia, any unresolved toxicities from prior therapy greater
             than Common Terminology Criteria for Adverse Events (CTCAE) grade 1 at the time of
             starting study treatment

          -  Spinal cord compression or brain metastases unless asymptomatic, treated and stable
             and not requiring steroids for at least 2 weeks prior to start of study treatment

          -  Concurrent use of endocrine therapy

          -  As judged by the investigator, any evidence of severe or uncontrolled systemic
             diseases, including active bleeding diatheses, or active infection including hepatitis
             B, hepatitis C and human immunodeficiency virus (HIV). Screening for chronic
             conditions is not required.

          -  Any of the following cardiac criteria:

               -  Any clinically important abnormalities in rhythm, known prolonged QTc, conduction
                  or morphology of resting ECG, complete left bundle branch block, third degree
                  heart block

               -  Experience of any of the following procedures or conditions in the preceding 6
                  months: coronary artery bypass graft, angioplasty, vascular stent, myocardial
                  infarction, angina pectoris, congestive heart failure NYHA Grade 2 or greater

               -  Uncontrolled hypotension - Systolic BP <90mmHg and/or diastolic BP <50mmHg

               -  Left ventricular ejection fraction (LVEF) below lower limit of normal for site

          -  Inadequate bone marrow reserve or organ function as demonstrated by any of the
             following laboratory values:

               -  Absolute neutrophil count < 1.5 x 109/L

               -  Platelet count < 100 x 109/L

               -  Hemoglobin < 9 g/L

               -  Alanine aminotransferase > 2.5 times the upper limit of normal (ULN)

               -  Aspartate aminotransferase > 2.5 times ULN

               -  Total bilirubin > 1.5 times ULN

               -  Creatinine >1.5 times ULN concurrent with creatinine clearance < 50 ml/min
                  (measured or calculated by Cockcroft and Gault equation); confirmation of
                  creatinine clearance is only required when creatinine is > 1.5 times ULN

               -  Proteinuria 3+ on dipstick analysis or >500mg/24 hours

               -  Sodium or potassium outside normal reference range for site

          -  Peripheral neuropathy grade 2 or greater

          -  Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to
             swallow the formulated product or previous significant bowel resection that would
             preclude adequate absorption Ipatasertib

          -  History of hypersensitivity to Ipatasertib, or drugs with a similar chemical structure
             or class to Ipatasertib

          -  Clinically significant abnormalities of glucose metabolism as defined by any of the
             following:

               -  Diagnosis of type I or type II diabetes mellitus requiring insulin

               -  A baseline fasting glucose value of ≥ 200 mg/dL (fasting glucose value to be
                  obtained only if non-fasting glucose >200mg/dL)

               -  Glycosylated hemoglobin (HbA1C) >7.5%

          -  Uncontrolled pleural effusion, pericardial effusion, or ascites

          -  Other malignancies within the past 3 years, with the exception of adequately resected
             basal or squamous carcinoma of the skin

          -  Clinically significant pulmonary symptoms or disease

          -  Judgment by the investigator that the patient should not participate in the study if
             the patient is unlikely to comply with study procedures, restrictions and requirements